[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose-metabolism-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose-metabolism-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,49,91,119,151,180,211,236,270,302,329,359,386,410,438,460,502,533,567,598],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100054307","phase-2-metabolic-modulation-to-enhance-insulin-sensitivity-and-mitochondrial-function-in-type-1-diabetes-metmod-t1d-100054307",false,"NCT07699380","METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)","MetMod-T1D","Inclusion Criteria:\n\n1. Adults ≥18 years to \\\u003C70 years of age with established T1D (duration ≥1 year)\n2. Currently on insulin therapy (multiple daily injections or insulin pump)\n3. HbA1c \\\u003C9.5%\n4. BMI 18.5-40 kg\u002Fm2\n5. On stable dose of RASB or statin, if indicated\n6. Willing and able to comply with all study procedures\n\nExclusion Criteria:\n\n1. History of pancreatic disease (including pancreatitis) or pancreatic surgery\n2. History of cardiovascular disease or stroke within the past 6 months\n3. History of heart failure per New York Heart Association criteria\n4. History of severe edema or salt restriction requirement\n5. Biliary disease or pathologies that may alter enterohepatic circulation of bile acids\n6. Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m²\n7. Liver disease (ALT\u002FAST \\>3x upper limit of normal \\[ULN\\])\n8. Pregnancy, breastfeeding, or planning pregnancy during the study period\n9. Known hypersensitivity to study drug components\n10. Abnormal baseline ECG\n11. Use of off label medications that affect insulin sensitivity within the past 1 month (e.g., metformin, GLP-1RA, SGLT2i, pioglitazone)\n12. Chronic use of anticoagulants\n13. Use of bile acid sequestering agents, inhibitors of bile acid transporters, bile acid derivatives, aluminum-based antacids, probenecid, pan-HDAC inhibitors, phase 2 metabolizing enzymes (e.g., uridine diphosphate glucuronosyl transferases), phase 1 metabolizing enzymes other than cytochrome P450 enzymes (CYPs), and OATP1B3\n14. Use of substrates of CYP1A2, CYP2C8, CYP2B6, CYP3A4, Organic Anion transporter 1, P-glycoprotein, and Breast Cancer Resistance Protein\n15. History of severe hypoglycemia requiring assistance within the past 3 months\n16. History of diabetic ketoacidosis (DKA) within the past 3 months\n17. Personal or family history of breast cancer or ovarian cancer\n18. Current participation in another clinical trial\n19. Any condition(s) found by the study team and confirmed with the Investigator that make it unsafe to participate","ALL","18 Years","69 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study is a randomized, double-blind, parallel-group clinical trial to examine the effects of 24 weeks of oral AMX0035 (sodium phenylbutyrate + taurursodiol) versus placebo in 60 adults with Type 1 Diabetes (T1D) (n=30 per arm). Enrollment will be distributed equally between the University of Washington and Amsterdam University Medical Center\u002FDiabetes Center Amsterdam. Participants will be recruited through diabetes research registries, local T1D clinics, and community outreach.",[27,28,29,30,31,32,33,34,35],"Type 1 Diabetes (T1D)","Metabolic Diseases","Glucose Metabolism Disorders","Endocrine System Diseases","Autoimmune Diseases","Immune System Diseases","Diabetes Melletus, Type 1","Nutritional and Metabolic Diseases","Combination Therapy","RECRUITING","2026-07-09",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":21},"2026-06",{"date":44,"type":21},"2029-12",{"name":46,"class":47},"University of Washington","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":77,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347","NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","65 Years",{"count":59,"type":21},130,[61],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[64,65,29,66,34,30,67,68,69,70,71,72,73,74,75,76],"Diabetes Mellitus, Type 2","Diabetes Melletus","Metabolic Disorders","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[78,69],"Ramadan","NOT_YET_RECRUITING","2026-06-18",{"date":82,"type":40},"2026-06-23",{"date":84,"type":21},"2026-07",{"date":86,"type":21},"2027-05",{"name":88,"class":89},"Eli Lilly and Company","INDUSTRY",37,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":48},"100445843","brain-metabolism-observed-at-3-tesla-or-7-tesla-in-health-and-metabolic-disease-100445843","NCT05085704","Brain Metabolism Observed at 3 Tesla or 7 Tesla in Health and Metabolic Disease","Inclusion Criteria:\n\n1. Subjects will be adolescents or adults, age 16-80 years in good general health (evidenced by normal vital signs and no acute signs or symptoms of illness) or with previously (not for this study) documented G1D (genetically confirmed).\n2. Ages 16 to 80\n3. Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included.\n\nExclusion Criteria:\n\n1. People or patients with uncontrolled seizure disorder, defined as grand mal (not absence) seizure in the preceding 3 months.\n2. Pregnant females will be excluded. A serum or urine pregnancy test will be administered to all females of child bearing potential within 24 hours of administration of the tracer and MRI scan. The pregnancy test will be communicated in person by the study PI. Positive results in subjects 17 years old or younger will be disclosed to parent\u002Fguardian only.\n3. Subjects with typical implanted orthopedic metal in bone may be considered for inclusion in a 7T scan providing the implant is not within the volume of the radio frequency coil. The PI and the AIRC Medical Director will discuss each case and determine eligibility.\n4. Persons with ICD, pacemakers, neurostimulators and other such devices will be excluded.\n5. Persons with claustrophobia are excluded.\n6. Persons with questionable ferrous implants, bullets, BB's, and shrapnel will be excluded.\n7. Subjects who are not fluent in English will be excluded because immediate cooperation and the ability to respond to instructions from the investigators are necessary.\n8. People following a ketogenic diet",true,"16 Years","80 Years",{"count":5,"type":21},"OBSERVATIONAL","The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla or 3 Tesla.",[104,29,105,106,107,108,109],"Glut1 Deficiency Syndrome 1","Epilepsy","Glut1 Deficiency Syndrome 1, Autosomal Recessive","Glucose Transporter Type 1 Deficiency Syndrome","Glucose Transporter Protein Type 1 Deficiency Syndrome","Glucose Transport Defect","2026-05-27",{"date":112,"type":40},"2026-06-01",{"date":114,"type":40},"2022-05-03",{"date":116,"type":21},"2029-08-01",{"name":118,"class":47},"Weill Medical College of Cornell University",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":138,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":149,"locationsCount":129},"100640765","phase-2-anakinra-for-the-treatment-of-postprandial-hypoglycemia-in-a-patient-with-total-gastrectomy-and-end-stage-renal-disease-100640765","NCT07580079","Anakinra for the Treatment of Postprandial Hypoglycemia in a Patient With Total Gastrectomy and End-Stage Renal Disease","Anakinra for the Treatment of Recurrent Postprandial Hypoglycemia After Total Gastrectomy in a Patient With End-Stage Renal Disease","AnPHy-ReD","This is an N-of-1 Trial, tailored-designed to a single participant.\n\n* total gastrectomy\n* severe episodes of postprandial hypoglycaemia after total gastrectomy","MALE",{"count":129,"type":21},1,[24],"Post-meal low blood sugar (postprandial hypoglycemia) is a common problem after certain stomach surgeries like gastric bypass or stomach removal. It usually happens 1 to 3 hours after eating and can cause symptoms such as tiredness, hunger, sweating, dizziness, trouble speaking, or even fainting. Right now, there is no approved medication for this condition-only a careful diet reduced in sugars and refined carbohydrates can sometimes help reduce symptoms.\n\nThe AnPHy-ReD study is a personalized research study, designed for just one patient. This patient is a 52-year-old man who has been struggling with severe post-meal low blood sugar ever since his stomach was removed due to tumor in 2017. He also has end-stage kidney disease and needs dialysis three times a week.\n\nThe study is being conducted at the Cantonal Hospital of Olten in Switzerland and lasts 10 weeks, including 24 study visits. Most of these visits will happen during the patient's regular dialysis sessions. For 6 weeks, the patient will take either the drug Anakinra or a placebo (a substance with no active ingredient), in a randomly chosen order. Neither the patient nor the doctors will know which one he is taking at any given time.\n\nDuring the study, the medical team will perform various tests, including physical check-ups and blood samples to look at sugar levels, various hormone levels and inflammation in the body. The patient will also wear a continuous glucose monitor (CGM) to track his blood sugar levels 24\u002F7. In addition, he will do several mixed meal tests-this means drinking a shake containing fats, proteins, and sugars during a study appointment to see in real time how his body processes food, with doctors measuring changes in blood sugar, hormone and inflammation markers over time. During the study duration any side effects or symptoms will be closely monitored.\n\nAt the end of the study, the team will compare the results between the times the patient took Anakinra and the times he took the placebo. This will help find out if Anakinra can reduce sharp drops in blood sugar after meals and improve his overall condition.",[133,134,135,29,136,137],"Postprandial Hypoglycemia","End-stage Renal Disease (ESRD)","Gastrectomy","Inflammation","Gastric Bypass Surgery",[133,139,140,141,142,136],"End-Stage Renal Disease","Anakinra","Gastric Bypass","IL-1 receptor antagonist","2026-05-05",{"date":145,"type":40},"2026-05-12",{"date":84,"type":21},{"date":148,"type":21},"2026-12",{"name":150,"class":47},"Marc Donath",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":97,"sex":16,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":129},"100362068","animal-and-plant-proteins-and-glucose-metabolism-100362068","NCT03994367","Animal and Plant Proteins and Glucose Metabolism","HP","Inclusion Criteria:\n\n* age: ≥21 and ≤70 years;\n* BMI: \\>24.5 and \\\u003C32.5 kg\u002Fm2;\n* habitual protein intake \\\u003C0.9 g\u002Fkg\u002Fday (assessed on 2 weekdays and 2 weekend days by using the HealthWatch 360 app); and\n* weight stable (i.e., ≤3% change) and untrained (≤150 min of structured exercise\u002Fweek) for at least 2 months before entering the study.\n\nExclusion Criteria:\n\n* prediabetes or type 2 diabetes;\n* evidence of chronic kidney disease by medical history or laboratory tests (glomerular filtration rate \\\u003C60 ml\u002Fmin\u002F1.73 m2 or an albumin to creatinine ratio in urine ≥30 mg\u002Fg);\n* vegetarians or vegans;\n* intolerance or allergies to ingredients in the metabolic meal or intervention diet;\n* take dietary supplements (e.g., pre- and probiotics, fiber, fish oil) or medications known to affect our study outcomes;\n* received antibiotic or antifungal treatment (which affect the microbiome and therefore microbial metabolite production) 2 months before entering the study;\n* consume tobacco products or excessive alcohol (women: \\>14 drinks\u002Fweek; men: \\>21 drinks\u002Fweek);\n* evidence of significant organ system dysfunction or diseases (e.g., cirrhosis), and\n* unwilling or unable to provide informed consent.","21 Years","70 Years",{"count":161,"type":21},100,[163],"NA","The goal of this proposal is to determine the effect of a high protein diet in which the increase in protein intake is derived from different sources (animal vs plant and protein-rich whole foods vs protein isolates) on: i) liver and muscle insulin sensitivity; ii) the metabolic response to a meal, and iii) 24-h plasma concentration profiles of glucose, glucoregulatory hormones, and protein-derived metabolites purported to cause metabolic dysfunction.",[166,167,29],"Metabolic Syndrome","Metabolic Syndrome, Protection Against",[169,170,171],"High Protein","Metabolism","Diet",{"date":173,"type":40},"2026-05-08",{"date":175,"type":40},"2019-07-12",{"date":177,"type":21},"2028-04-25",{"name":179,"class":47},"University of Missouri-Columbia",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":191,"conditions":192,"keywords":196,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":207,"leadSponsor":209,"locationsCount":129},"100639957","specificities-of-atypical-non-autoimmune-diabetes-anaid-in-the-french-west-indies-100639957","NCT07576374","Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies","Epidemiological, Clinical, Biological and Genetic Specificities of Atypical Non-AutoImmune Diabetes (ANAID) in the French West Indies","DiAGeNA","Inclusion Criteria:\n\nPhenotypic criteria :\n\nSubjects from Indian or African Ancestry self-declared\n\nAge criteria at diagnosis:\n\nEarly onset of diabetes: patient aged between 18 and 47 years at the time of diagnosis of diabetes Clinical criteria: at least 2 criteria Labeled type 2 diabetic\n\nPatient hospitalized for:\n\nKetoacid decompensation Significant weight loss (more than 10% in less than 6 months) without obvious etiology Lipodystrophic \u002F lipoatrophic appearance Presence of an associated myopathy or deafness Presence of early inaugural nephropathy or within 3 years after diagnosis Presence of early inaugural heart disease or within 3 years after diagnosis Poor response to non-insulin treatments despite good adherence\n\nBiological criteria:\n\nAbsent T1D autoantibodies:\n\nAnti-islet antibodies (ICA) Anti-IA2 antibodies Anti-insulin antibodies Anti-ZnT8 antibodies Anti-GAD antibodies\n\nOther criteria:\n\nInformed consent signed by the patient\n\nExclusion Criteria:\n\nType 1 diabetes (T1D) Presence of T1D antibodies Secondary diabetes (pancreas diseases, endocrine diseases, drug intake, infection) Other associated autoimmune pathologies Pregnancy Refusal to participate","47 Years",{"count":190,"type":21},118,"Genetics variants could be involved in atypical non-autoimmune diabetes revealed by ketoacidosis. The objective of this research will be to determine the relationships between the genetic variants already described in known monogenic diabetes or identified as involved in glucose metabolism and its regulation, in insulin signaling pathways or in insulin secretion itself in subjects of African and Indian ancestry with atypical forms of non autoimmune diabetes.",[28,193,194,195,29],"Diabetes Mellitus (Type 2)","Genetic Variation","Genetic Profile",[197,198,199,200,201,202,203],"Genetic diagnosis","Monogenic diabetes","Exome sequencing","Pathogenic variant","Ketoacidosis","Afro-Caribbean","African and Indian ancestry","2026-05-04",{"date":173,"type":40},{"date":42,"type":21},{"date":208,"type":21},"2029-09",{"name":210,"class":47},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":97,"sex":16,"minAge":158,"maxAge":159,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":129},"100327259","phase-2-regulation-of-endogenous-glucose-production-by-central-katp-channels-100327259","NCT03540758","Regulation of Endogenous Glucose Production by Central KATP Channels","Inclusion Criteria:\n\nFor healthy (non-diabetic) participants:\n\n* Age: 21-70 years old\n* Body Mass Index (BMI) under 40 kg\u002Fm\\^2\n* Negative drug screen (see below)\n* Normal Hemoglobin A1c (HbA1c) and fasting glucose\n* In general good health (see below for exclusions)\n* Not participating in any other research study besides those done by the study team\n\nFor T2D participants:\n\n* Age: 21-70 years old\n* BMI under 40 kg\u002Fm\\^2\n* Stable and moderate-to-poor glycemic control (HbA1c: 8.0-12.0%)\n* Negative drug screen (see below)\n* Not suffering from a previously diagnosed proliferative retinopathy, significant diabetic renal disease (urinary microalbumin \\\u003C100 μg\u002Fdl) or severe peripheral neuropathy (including cardiovascular and gastrointestinal autonomic neuropathy) per medical history\n* Diabetic subjects will be otherwise in good health (see below for exclusions), taking no medications that might affect study eligibility based on review by study doctor, and not participating in any other research study besides those done by the study team\n\nExclusion Criteria:\n\n* Age: Under 21 or over 70 years old\n* BMI: \\>40 kg\u002Fm\\^2 for Type 2 Diabetes (T2D) and Non-Diabetic (ND) subjects\n* Blood pressure \\>150\u002F90 or \\\u003C90\u002F60 on more than one occasion\n* Severe polydipsia and polyuria (in subjects with T2D). Since polydipsia and polyuria are common symptoms of T2D, the distinction \"severe\" denotes that the subject indicates a worsening in the symptoms and\u002For an experience of discomfort related to the symptoms at the time of screening and\u002For at the time of withdrawal from the medications\n* Urine microalbumin: \\>300 mg\u002Fg of creatinine (in subjects with T2D)\n* Uncontrolled hyperlipidemia defined as Triglycerides (TG) \\> 400 mg\u002FdL and\u002For Total Cholesterol \\>300 mg\u002FdL\n* Clinically significant liver dysfunction including thrombocytopenia (platelets \\\u003C100,000\u002FuL), anemia (as below), hypoalbuminemia (\\\u003C3.5 g\u002FdL), coagulopathy (INR \\> 1.5), and\u002For liver enzymes more than 3 times the upper limit of normal\n* Clinically significant kidney dysfunction, Glomerular Filtration Rate (GFR): \\\u003C60 mg\u002FdL\n* Clinically significant anemia. Prospective subjects with hemoglobin below the lower limit of 12 g\u002Fdl for for men and 11 g\u002FdL for women will be assessed with history and physical exam to rule out clinically significant anemia, defined as an individual with symptoms (e.g., fatigue, weakness, shortness of breath, palpitations), signs (pallor, brittle nails etc.), or currently under treatment for anemia. In the absence of a documented hemoglobin decrease or iron deficiency, subjects will not be excluded\n* Clinically significant leukocytosis or leukopenia\n* Clinically significant thrombocytopenia or thrombocytosis\n* Coagulopathy\n* Urine drug screen positive for any of the following: amphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, oxycodone, phencyclidine (PCP). Amphetamines, oxycodone, opiates, methadone, and benzodiazepines have been shown to affect glucose metabolism (increased glycemia, increased fasting insulin levels, delayed insulin response to food ingestion, insulin deficiency). As the drug test available in the Clinical Research Center (CRC) is a 7-drug panel, the investigator team cannot specifically choose which drugs are screened for. Additionally, in the interest of selecting patients on the basis of their reliability and dependability, the investigator team would like to exclude participants using illicit drugs. Occasional use of cannabis (once or twice per week) is not an exclusion factor. If the test is read as \"indeterminate\" it will be repeated at the bedside and an additional sample will be sent to the lab. Decision to enroll subject that day prior to results from lab being available will be decided on a case-by-case basis, i.e., when all previous drug testing had been negative and clinical suspicion is very low\n* Urinalysis: Clinically significant abnormalities\n* Clinically significant electrolyte abnormalities\n* Smoking \\>10 cigarettes\u002Fday\n* Alcohol: Men \\>14 drinks\u002Fweek or \\>4 drinks\u002Fday, Women \\>7 drinks\u002Fweek or \\>3 drinks\u002Fday\n* History of chronic liver disease, active hepatitis infection, HIV\u002FAIDS, chronic kidney disease (stage 3 or greater), active cancer, cardiovascular disease or other heart disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle disease\n* Surgeries that involve removal of endocrine glands except for thyroidectomy (if euthyroid on thyroid hormone replacement - if such history free thyroxine (fT4) and Thyroid Stimulating Hormone (TSH) will be checked)\n* Pregnant women\n* Subject enrolled in another study less than one month prior to the anticipated start date of the proposed study, besides those done by our group\n* Family history of premature cardiac death\n* Allergies to medication administered during study\n* Uncontrolled psychiatric disorders\n* Any condition which in the opinion of the PI makes the subject ill suited for participation in the study",{"count":161,"type":21},[24],"Type 2 diabetes (T2D) affects the ability of the body to process glucose (sugar). Under fasting conditions, the liver is able to make sugar to maintain glucose levels in an important process called endogenous glucose production (EGP). Previous studies suggest that the central nervous system (CNS), including the brain, helps to regulate levels of glucose in the body by communicating with the liver. This process can be impaired in people with type 2 diabetes, and can contribute to the high level of glucose seen in these individuals.\n\nThe purpose of this study is to understand how activating control centers of the brain with a medication called diazoxide can affect how much glucose (sugar) is made by the liver. This is particularly important for people with diabetes who have very high production of glucose, which in turn can lead to diabetes complications.",[221,29],"Diabetes Mellitus",[223,224,225,226],"Central KATP Channels","diabetes","diazoxide","endogenous glucose production","2026-04-23",{"date":229,"type":40},"2026-04-28",{"date":231,"type":40},"2018-08-01",{"date":233,"type":21},"2027-04",{"name":235,"class":47},"Albert Einstein College of Medicine",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":97,"sex":243,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":258,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":48},"100480983","cognitive-behavioral-therapy-and-exercise-training-in-adolescents-at-risk-for-type-2-diabetes-100480983","NCT05543083","Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes","CBTeX","Inclusion Criteria:\n\n* Female\n* Age 12-17 years\n* Body Mass Index (BMI)\\>= 85 for age and sex\n* Type 2 Diabetes (T2D) first-or second-degree relative\n* Center for Epidemiologic Studies Depression Scale (CES-D) total score \\>=21\n\nExclusion Criteria:\n\n* T2D\u002F Type 1 Diabetes (T1D) or any major medical condition (e.g. cardiovascular, renal) that would prohibit the ability to participate in exercise training\n* Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) conduct disorder, substance abuse\u002F dependence, obsessive compulsive disorder, panic attacks, post-traumatic stress disorder, anorexia\u002Fbulimia, \\& schizophrenia\n* Insulin sensitizers, weight loss medications \\& chronic steroids\n* Structured weight loss treatment or bariatric surgery\n* Pregnancy, nursing","FEMALE","12 Years","17 Years",{"count":247,"type":21},300,[163],"The investigators are doing this study to learn more about how to prevent type 2 diabetes in teenage girls. The purpose of this study is to find out if taking part in a cognitive-behavioral therapy group, exercise training group, or a combination of cognitive-behavioral therapy and exercise training groups, decreases stress, improves mood, increases physical activity and physical fitness, and decreases insulin resistance among teenagers at risk for diabetes.",[251,252,253,254,255,256,29,257],"Insulin Resistance","Depression","Depressive Disorder","Mood Disorders","Mental Disorder in Adolescence","Hyperinsulinism","Metabolic Disease",[259,260],"Adolescent Type 2 Diabetes Prevention","Exercise Training","2026-04-17",{"date":263,"type":40},"2026-04-22",{"date":265,"type":40},"2023-06-02",{"date":267,"type":21},"2029-03-31",{"name":269,"class":47},"Colorado State University",{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":277,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100615112","the-cgm-ogtt-glycemic-homeostasis-study-100615112","NCT07288372","The CGM-OGTT Glycemic Homeostasis Study","An Exploratory Investigation Into the Mechanism of Glycemic Homeostasis Regulation Under the Synergistic Conditions of Continuous Glucose Monitoring (CGM) and Oral Glucose Tolerance Test (OGTT)","Inclusion Criteria:\n\nTo be eligible to participate in this study, an individual must meet ALL of the following criteria:\n\n* Is aged between 18 and 70 years, inclusive.\n* And meets at least ONE of the following conditions:\n\n  * Presents with diabetes-related clinical symptoms or signs (e.g., unexplained ·polydipsia, polyphagia, polyuria, weight loss) and has been advised by a ·clinician to undergo an OGTT for diagnostic clarification.\n  * Has indicators of abnormal glucose metabolism:Impaired Fasting Glucose (IFG): Fasting venous plasma glucose ≥ 6.1 mmol\u002FL and \\\u003C 7.0 mmol\u002FL.and\u002For Glycated hemoglobin (HbA1c) in the pre-diabetes range of 5.7% to 6.4%.\n  * Has at least one of the following diabetes risk factors:Body Mass Index (BMI) ≥ 24 kg\u002Fm²；Has a first-degree relative (parent, sibling, or child) with a history of diabetes；Has a history of hypertension (or undergoing antihypertensive treatment) or dyslipidemia.\n\nExclusion Criteria:\n\n* An individual who meets ANY of the following criteria will be excluded from participation in this study:\n* Previously diagnosed with diabetes.\n* Use of medications that significantly affect glucose metabolism or gastrointestinal hormones (e.g., GLP-1 receptor agonists, DPP-4 inhibitors, glucocorticoids) within a specified washout period prior to enrollment.\n* History of gastrointestinal surgery (e.g., gastrectomy) or chronic pancreatic disease.\n* Presence of severe hepatic or renal impairment (e.g., ALT \\> 3 times the upper limit of normal, or eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m²).\n* Pregnant or lactating women, or women planning to become pregnant during the study period.\n* Known allergy to soy (as the standardized meal may contain soy-based components).",{"count":278,"type":21},225,"This is a prospective, exploratory, observational study aimed at investigating the mechanisms of glycemic homeostasis by comparing continuous glucose monitoring (CGM) data with results from the oral glucose tolerance test (OGTT).\n\nThe study plans to enroll approximately 225 participants aged 18-70 years who are at risk for or suspected of having glucose metabolism disorders, but without a prior diagnosis of diabetes. Participants will be equipped with a blinded CGM device for 10-14 days. During this period, they will perform two standardized mixed-meal tolerance tests (MMTT) at home. Subsequently, they will undergo a standard 75g OGTT at the hospital, where blood samples will be collected at multiple time points to measure glucose, insulin, C-peptide, and gastrointestinal hormones (GLP-1, GIP).\n\nBased on the 2-hour blood glucose value from the OGTT, participants will be naturally categorized into three groups for comparative analysis: Normal Glucose Tolerance (NGT), Pre-diabetes (Pre-DM), and Newly Diagnosed Type 2 Diabetes (T2DM).\n\nThe primary objective is to establish a quantitative relationship between CGM-derived parameters (e.g., glycemic variability, time-in-range) after the MMTT and the OGTT diagnostic results. Secondary objectives include assessing the feasibility and correlation between home-based MMTT and standard OGTT, exploring the impact of gastrointestinal hormone responses on daily glucose fluctuations, and investigating the association between postprandial glucose dynamics and vascular reactivity (e.g., postprandial hypotension).",[281,29],"Type 2 Diabetes",[283,284,285,286,287,288,289,290,291,292],"Continuous Glucose Monitoring","CGM","Oral Glucose Tolerance Test","OGTT","Mixed-Meal Tolerance Test","Glycemic Variability","Incretins","Home-Based Testing","GLP-1","GIP","2025-12-21",{"date":295,"type":40},"2025-12-23",{"date":297,"type":21},"2025-12-18",{"date":299,"type":21},"2027-08-10",{"name":301,"class":47},"Shanghai 6th People's Hospital",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":311,"conditions":312,"keywords":316,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":328},"100481074","rare-and-atypical-diabetes-network-100481074","NCT05544266","Rare and Atypical Diabetes Network","RADIANT","Inclusion Criteria:\n\nThe following criteria or phenotypes will be considered for suspecting \"atypical\" participants:\n\n* Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese\n* Mendelian pattern, especially with early onset (\\\u003C18 years old)\n* Syndromic (multiple systems involved)\n* Lipodystrophic\n* Extremes of BMI\n* \"Mitochondrial\" characteristics (e.g., myopathy, hearing deficits)\n* Non-progressive\n* Rapidly progressive (\"fulminant\")\n* Low insulin requirements (\\\u003C0.5 u\u002Fkg\u002Fday)\n* Cyclical hyperglycemia with periods of remission\n* Lean persons with polycystic ovarian syndrome (PCOS)\n* History of gestational diabetes (GDM) when lean\n* Lean insulin-resistant persons\n* If islet autoantibodies and beta-cell function parameters have been measured (where \"A\" = islet cell autoantibodies, \"B\" = beta-cell function):\n\noA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)\n\nExclusion Criteria:\n\n* Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes\n* Refusal of consent for genetic testing\n* Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)\n* Women who are currently pregnant",{"count":310,"type":21},2000,"RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.\n\nThe objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:\n\n1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes.\n2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes.\n3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.",[221,313,314,29,257,315,30],"Diabetes Mellitus Progression","Glucose Intolerance","Endocrine; Complications",[307,317,318,314],"Atypical Diabetes","Rare Diabetes","2025-08-11",{"date":321,"type":40},"2025-08-14",{"date":323,"type":40},"2020-09-30",{"date":325,"type":21},"2030-09",{"name":327,"class":47},"University of South Florida",13,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":11,"sex":243,"minAge":17,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":341,"conditions":342,"keywords":346,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":358},"100557259","phase-2-inhaled-insulin-vs-rapid-acting-injections-for-post-meal-glucose-control-in-women-with-gestational-diabetes-100557259","NCT06535789","Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes","The Safety and Efficacy of Rapid Acting Inhaled Technosphere Insulin (Afrezza) Compared With Subcutaneous Insulin to Achieve Pregnancy-Specific Postprandial Targets Among Patients With Gestational Diabetes","INHALE-GDM","Inclusion Criteria\n\n1. Ability to provide informed consent for study participation\n2. Age ≥18 years and \\\u003C41 years old\n3. Singleton pregnancy at 24-34 weeks gestation\n4. Diagnosis of GDM via standard 1-step or 2-step criteria\n5. Treated with an insulin regimen that includes a RAA bolus of any type for breakfast, with a dose \\\u003C20 units\n6. Pre-pregnancy or first trimester body mass index (BMI) 25-45\n7. Investigator believes that the protocol can be safely conducted by the participant\n8. Able to read and speak English\n\nExclusion Criteria\n\n1. Type 1 diabetes or type 2 diabetes\n2. HbA1c ≥ 6.5%, FBG ≥125 mg\u002Fdl or 2-hr glucose ≥200 mg\u002FdL on 75g OGTT, or random plasma glucose ≥200 mg\u002FdL (consistent with pre-existing diabetes and not GDM diagnosis)\n3. Current use of any non-insulin glucose lowering medication\n4. Using TI (Afrezza), regular insulin, or ≥20 RAA units at breakfast (NPH is permissible)\n5. Peak expiratory flow \\\u003C80% predicted as measured by peak flow meter\n6. Recent history of asthma (defined as using any medications to treat asthma within the last year), chronic obstructive pulmonary disease (COPD), or any other clinically important pulmonary disease (e.g., cystic fibrosis or bronchopulmonary dysplasia), or significant congenital or acquired cardiopulmonary disease as judged by the Investigator\n7. Smoking (includes cigarettes, cigars, pipes, and\u002For vaping devices) within 90 days prior to screening\n8. History or current diagnosis of lung cancer\n9. Current or anticipated use of oral, inhaled or injectable glucocorticoids during the time period of the trial (topical glucocorticoid use is acceptable)\n10. Renal or hepatic impairment that in the investigator's judgment poses a safety risk for the study participant\n11. Recurrent Level 2 (blood glucose \\\u003C54 mg\u002FdL) or Level 3 severe hypoglycemia events\n12. Current use of non-cardio-selective beta blockers\n13. Being a member of the study team, having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study Investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial","40 Years",{"count":339,"type":21},30,[24,61],"Pregnant women aged 18-40 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect their blood sugar after they eat. These women usually use a rapid-acting insulin analog (RAA) that's injected to control their blood sugar before and after meals. They will come to the clinic for two meal sessions. For the first meal, we will randomly decide if they will use the usual RAA insulin or a newer inhaled insulin called technosphere insulin (TI). They will use the other type of insulin for their second meal. After each meal, we will compare their blood sugar levels.",[343,344,29,345],"Diabetes, Gestational","Pregnancy Complications","Glucose Intolerance During Pregnancy",[347,348],"Gestational Diabetes","Inhaled Insulin","2025-05-13",{"date":351,"type":40},"2025-05-15",{"date":353,"type":21},"2025-05",{"date":355,"type":21},"2025-07",{"name":357,"class":47},"Jaeb Center for Health Research",5,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":97,"sex":243,"minAge":158,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":129},"100445484","integrated-hyperglycaemia-incentivised-postnatal-surveillance-study-i-hips-100445484","NCT05081037","Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)","Lifestyle Interventions to Prevent Postpartum Type II Diabetes Mellitus in Asian Women With a History of Gestational Diabetes Mellitus","I-HIPS","Inclusion Criteria:\n\n1. Women diagnosed antenatally with GDM by IADPSG criteria (15)\n2. Normal 6 weeks post-natal OGTT\n3. BMI range from 20-40\n4. Physically fit to participate in moderate intensity walking\n\nExclusion Criteria:\n\n1. Women with serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days\n2. Women who have any other serious chronic disease such as chronic kidney disease and heart disease","45 Years",{"count":247,"type":21},[163],"This study aims to test the following hypotheses in a randomized controlled trial of post-partum women with a history of gestational diabetes mellitus (GDM) that will be followed up for up to 4 years:\n\n1. Post-partum pregnancy is ideal for behavioural modification and adopting a healthy lifestyle. Using the continous glucose monitoring (CGM) sensor and an exercise tracker will promote self-motivation and awareness by positive reinforcement and behavioural changes to improve diet, control body weight and increase physical activity in this group of post-partum women who are at high risk for developing Type II Diabetes.\n2. The use of the continous glycose monitoring (CGM) sensor and exercise tracker will motivate women to modify their dietary food intake and physical activity over time, reducing their cardiovascular risk factors for developing metabolic syndrome by lowering their baseline blood pressure, BMI, reducing their waist circumference and body fat mass, glycaemic levels and fasting lipids within the targeted healthy range.\n3. There will be an increase in the quality adjusted life years (QALYs) gained based on improvements in HbA1C and other proximal outcomes at the end of the trial.",[347,29,257],[373,374,375],"gestational diabetes","post-partum intervention","Body composition","2025-04-15",{"date":378,"type":40},"2025-04-17",{"date":380,"type":40},"2021-09-06",{"date":382,"type":21},"2026-05-26",{"name":384,"class":385},"KK Women's and Children's Hospital","OTHER_GOV",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":129},"100587254","early-phase-1-metabolic-effects-of-endogenous-bile-acids-after-gastric-bypass-surgery-100587254","NCT06925997","Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery","Bile-bar","Inclusion Criteria:\n\nIntervention group\n\n* RYGB-operated ≥ 18 months prior to inclusion\n* History of diabetes prior to RYGB (HbA1c ≥48 mmol\u002Fmol or use of antidiabetic medication)\n* HbA1c \\\u003C58 mmol\u002Fmol on no antidiabetic medication or metformin alone\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion\n\nControl group A\n\n* No history of diabetes\n* HbA1c \\\u003C48 mmol\u002Fmol at time of inclusion\n* Fasting plasma glucose \\\u003C 7.0 mmol\u002FL at time of inclusion\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion Control group B\n* Type 2 diabetes (HbA1c ≥48 mmol\u002Fmol or use of antidiabetic medication at time of inclusion)\n* Weight change \\\u003C ±3 kg for \\>3 months at time of inclusion\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Haemoglobin \\\u003C 6.5 mmol\u002FL at time of inclusion\n* Fasting plasma glucose \\> 10.0 mmol\u002FL at time of inclusion\n* Prior cholecystectomy\n* Chronic or tendency to diarrhoea",{"count":394,"type":21},18,[396],"EARLY_PHASE1","Non-randomized, open-label, parallel-group clinical study evaluating the effects of endogenous bile acids on changes in plasma fibroblast growth factor-19 (FGF-19) and glucose metabolism by extended depletion of circulating bile acids using colesevelam as an experimental tool in subjects operated with gastric by-pass (RYGB).",[399,400,29],"Bariatric Surgery Candidate","Bile Acid, Elevated Serum","2025-04-11",{"date":403,"type":40},"2025-04-13",{"date":405,"type":40},"2024-05-02",{"date":407,"type":21},"2028-12",{"name":409,"class":47},"Hvidovre University Hospital",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":419,"briefSummary":420,"conditions":421,"keywords":425,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":129},"100583627","postprandial-metabolome-and-metabolic-flexibility-100583627","NCT06878781","Postprandial Metabolome and Metabolic Flexibility","Standardized Meals With Different Macronutrient Ratios on the Postprandial Metabolome and Metabolic Flexibility","Inclusion Criteria:\n\n* be over 18 years of age and under 30 years of age;\n* without active drug addictions: smoking, alcoholism, and\u002For drug addiction;\n* in female subjects: regular menstrual cycles;\n* give written consent for their inclusion in the study.\n\nExclusion Criteria:\n\n* subjects with any pathology that requires medication or special treatment, such as type 2 diabetes mellitus, high blood pressure, dyslipidemia, polycystic ovary syn-drome, autoimmune, thyroid, kidney, neurological diseases, and cancer;\n* pregnant or lactating women;\n* subjects with problems with chewing, salivation, and swallowing.\n\nElimination criteria:\n\n* subjects who only have samples (blood and calorimetry) from one study period (fasting or postprandial);\n* subjects who only have samples (blood and calorimetry) of a metabolic challenge;\n* subjects who have an infection at the scheduled appointment;\n* subjects who withdraw their informed consent","30 Years",{"count":247,"type":21},[163],"Metabolic flexibility is a process in which the body can switch energy substrates in different physiological states. This flexibility plays an important role in an individual's health because losing it increases the risk of obesity, metabolic syndrome, insulin resistance, and type 2 diabetes. Considering that humans spend most of their awakening hours in a postprandial (PP) state, an organism's metabolic flexibility (MF) to respond to a standardized meal's consumption would provide information on the individual's metabolic health. The PP response to glucose following an oral glucose tolerance test or consumption of a high-carbohydrate meal is well described; however, few studies assess the FM and PP metabolome using mixed meals with different macronutrients. The investigators address how metabolic flexibility and metabolome change after consuming standardized meals with different macronutrient ratios. Data collection includes clinical and diet information, indirect calorimetry, and capillary blood sampling during fasting and after consumption of standardized meals. Samples are collected weekly for one month. The data will determine the metabolic flexibility and metabolome after consuming standardized meals with different macronutrient ratios.",[69,422,423,29,424],"Postprandial Hyperglycemia","Lipid Metabolism Disorders","Insulin Sensitivity",[426,427,428],"metabolic flexibility","postprandial response","mixed meals","2025-03-10",{"date":431,"type":40},"2025-03-17",{"date":433,"type":40},"2024-01-08",{"date":435,"type":21},"2026-12-18",{"name":437,"class":385},"Instituto Nacional de Medicina Genomica",{"id":439,"slug":440,"hasResults":11,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":446,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":129},"100574767","food-orders-on-blood-glucose-and-fuel-use-at-rest-100574767","NCT06763562","Food Orders on Blood Glucose and Fuel Use At Rest","The Impact of Different Food Orders on Blood Glucose and Fuel Use At Rest","Inclusion Criteria:\n\n* 18-70 years old\n* Free from any allergy or condition that precluding consumption of edamame, butter, and rice\n* Not currently pregnant\n* Free of any medical conditions requiring the use of insulin\n* Have no history of bariatric surgery\n* Have no implanted electrical devices such as a pacemaker\n\nExclusion Criteria:\n\n* Younger than 18 and older than 70 years old\n* Having an allergy or condition that precludes consumption of edamame, butter, and rice\n* Currently pregnant\n* Any medical conditions requiring the use of insulin\n* A history of bariatric surgery\n* Having an implanted electrical device such as a pacemaker",{"count":20,"type":21},[163],"Consuming a carbohydrate-rich food as the final food in a meal, as compared to the first food in a meal, has been shown to reduce blood glucose levels after eating in both diabetes patients and in healthy controls. However, gaps remain in the literature in this area of research, and currently little is known about how substrate (fuel) use is impacted by altering food order. In addition, most studies to date have used a mix of meat and plant foods, while little research has focused exclusively on vegetarian foods. This randomized experiment will examine how altering the order of foods eaten in a vegetarian meal impacts blood glucose and fuel utilization at rest.",[29,449,450],"Hunger","Fat Burn","2025-02-16",{"date":453,"type":40},"2025-02-19",{"date":455,"type":40},"2025-01-05",{"date":457,"type":21},"2026-06-30",{"name":459,"class":47},"Old Dominion University",{"id":461,"slug":462,"hasResults":11,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":488,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":129},"100567960","clinical-trial-assessing-human-placental-membrane-products-and-standard-of-care-versus-standard-of-care-in-nonhealing-dfus-and-vlus-100567960","NCT06674980","Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs","A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.","C5CAMP","Inclusion Criteria for DFU:\n\n1. At least 18 years of age or older.\n2. Must have diagnosis of type 1 or 2 Diabetes mellitus.\n3. At enrollment, subject must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with the imaging device.\n4. Must have a target ulcer that has been present for a minimum of 4 weeks and maximum of 52 weeks of standard of care, prior to screening visit.\n5. Target ulcer located on the foot with at least 50% of the ulcer below the malleolus.\n6. Target ulcer that is Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the medial aspect of the malleolus. The ulcer may not include exposed tendon or bone.\n7. Subject's affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and \\\u003C= 1.3\n   2. TBI \\>= 0.6\n   3. TCOM \\>= 40 mmHg\n   4. PVR: biphasic\n8. If subject has two or more ulcers, they must be separated by 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n9. Target ulcer must be located on the plantar aspect of the foot and must be offloaded for at least 14 days prior to enrollment.\n10. Subject must consent to using the prescribed offloading method for the duration of the study.\n11. Subject must agree to attend weekly study visits.\n12. Subject must be willing and able to participate in the consent process.\n\nExclusion Criteria for DFU:\n\n1. Subject is known to have a life expectancy of \\\u003C 6 months.\n2. Subject's target ulcer is not secondary to diabetes.\n3. Target ulcer is infected or there is cellulitis in the surrounding skin.\n4. Target ulcer exposes tendon or bone.\n5. Evidence of osteomyelitis complicating the target ulcer.\n6. Infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n7. The subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n8. Subject is taking hydroxyurea.\n9. Subject has applied topical steroids to the ulcer surface within one month of initial screening.\n10. Subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n11. Subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n12. The surface area of the subject's target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n13. The surface area measurement of the subject's target ulcer decreases by 20% or more during the active 2-week screening phase.\n14. Subject has acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n15. Subject is a woman who is pregnant or considering becoming pregnant in the next 6 months.\n16. Subject has end stage renal disease requiring dialysis.\n17. Subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.\n18. The subject, in opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments.\n19. Subject was treated with hyperbaric oxygen therapy or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to screening.\n20. Subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n\nInclusion Criteria for VLU:\n\nPotential subjects are required to meet all the following criteria for enrollment in the study.\n\n1. Subjects must be at least 18 years of age or older.\n2. At randomization subjects must have a target ulcer with a minimum surface area of 0.7 cm2 and a maximum surface area of 20 cm2 measured post-debridement.\n3. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.\n4. No visible signs of healing objectively, less than 40% reduction in wound size in the last 4 weeks.\n5. The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:\n\n   1. ABI between 0.7 and ≤ 1.3;\n   2. TBI ≥ 0.6;\n   3. TCOM ≥ 40 mmHg;\n   4. PVR: biphasic.\n6. If the potential subject has two or more ulcers, they must be separated by at least 2 cm post-debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.\n7. The potential subject must agree to attend the weekly study visits required by the protocol.\n8. The potential subject must be willing and able to participate in the informed consent process.\n\nExclusion Criteria for VLU:\n\n1. The potential subject is known to have a life expectancy of \\\u003C 6 months.\n2. The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin.\n3. The target ulcer exposes tendon or bone.\n4. There is evidence of osteomyelitis complicating the target ulcer.\n5. The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n6. The potential subject has applied topical steroids to the ulcer surface within one month of initial screening.\n7. The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit.\n8. The surface area of the target ulcer has reduced in size by more than 20% in the 2 weeks prior to the initial screening visit (\"historical\" run-in period). Imaging Device is not required for measurements taken during the historical run-in period (e.g., calculating surface area using length X width is acceptable).\n9. The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC.\n10. Women who are pregnant or considering becoming pregnant within the next 6 months.\n11. The potential subject has end stage renal disease requiring dialysis.\n12. Participation in a clinical trial involving treatment with an investigational product within the previous 30 days.\n13. A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n14. The potential subject was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit.\n15. The subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n16. A subject has a wound with active or latent infection is excluded.\n17. A subject with a disorder that would create unacceptable risk of post-operative complications is excluded.",{"count":469,"type":21},177,[163],"The purpose of the study is to evaluate the efficacy of multiple human placental membrane products and Standard of Care (SOC) versus SOC alone in the management of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) over 12 weeks using a modified platform trial design.",[473,221,29,28,474,475,476,477,478,479,480,481,482,483,484,485,64,486,487],"Pathologic Processes","Endocrine System Disease","Diabetic Angiopathies","Vascular Diseases","Cardiovascular Diseases","Leg Ulcer","Skin Ulcer","Skin Diseases","Diabetes Complications","Diabetic Neuropathies","Foot Diseases","Diabetic Foot","Foot Ulcer","Ulcer","Foot Ulcer Unhealed",[489,490,491,492,493],"Human Placental Membrane (HPM)","Diabetic Foot Ulcer (DFU)","Venous Leg Ulcer (VLU)","Cellular, Acellular, and Matrix-like Product (CAMP)","Cellular and\u002For Tissue-Based Product (CTP)","2024-12-20",{"date":496,"type":40},"2024-12-27",{"date":494,"type":40},{"date":499,"type":21},"2027-01-22",{"name":501,"class":89},"C5 Biomedical",{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":97,"sex":16,"minAge":17,"maxAge":509,"enrollmentInfo":510,"targetDuration":4,"studyType":22,"phases":512,"briefSummary":513,"conditions":514,"keywords":517,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":129},"100520035","relationship-between-individual-effect-of-diet-on-postprandial-glycemia-and-gut-microbiome-profile-in-healthy-subjects-100520035","NCT06051318","Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects","Individual Effect of Diet on Postprandial Glycemic Response and Its Relationship with Gut Microbiome Profile in Healthy Subjects: Protocol for a Series of Randomized N-of-1 Trials","Inclusion Criteria:\n\n* BMI \\> 18.5 and \\\u003C 30\n* Willing to use an intradermal continuous glucose monitoring sensor during the 10-day study\n* Own a mobile phone with NFC technology\n* Willing to provide a fecal swab sample and a stool sample\n* Understanding, agreement, and signing of the approved Informed Consent Form (ICF) by the Ethics Committee (CEP)\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Diagnosis of any gastrointestinal disorder or disease (Irritable Bowel Syndrome, Ulcerative Colitis, Crohn's Disease)\n* Intolerance or allergy to any diet ingredient\n* Autoimmune disorder (Lupus, Type 1 Diabetes, Celiac Disease) or infectious disease\n* Diabetes diagnosis\n* Cancer diagnosis, acute myocardial infarction, or stroke in the last 6 months\n* Use of hypoglycemic medication\n* Use of proton pump inhibitors, immunosuppressants, or antimicrobials in the last 3 months\n* Use of laxative medications in the last 30 days\n* Underwent invasive procedures or surgery in the last 6 months\n* Admission to ICU in the last 2 years\n* Participation in any experimental study or ingestion of any experimental drug within twelve months prior to the start of this study, in accordance with RDC 251\u002F97\n* Inability to read and understand the informed consent form","60 Years",{"count":511,"type":21},80,[163],"When all the food we eat is digested, it will increase blood glucose. Two people can have different glucose blood levels to the same food and one reason can be bacteria live in our gut. There are more than a thousand bacteria species in our gastrointestinal tract that have an important role in the proper functioning of our body, so our gut microbiome is a key piece for our nutrition and blood glucose control.\n\nNowadays, one of the major public health concerns is the rise of people with diabetes (a disease characterized by an increase in blood glucose) and the increase in obesity, in which one of several risks is diabetes. There are multiple reasons for people develop those diseases, however, some care on diet management can prevent, delay, or improve the effects of these illnesses. Therefore, this study proposes studying the blood glucose variation between healthy volunteers and if there is a relationship between that variation and the intestinal bacteria present. These results can help doctors and nutritionists elaborate a personalized diet for people who need blood glucose level control.\n\nThe investigators are recruiting volunteers aged 18 to 60, healthy, living at Florianopolis and the surroundings to participate in this crossover randomized N-of-1 study. The participants must collect fecal samples. After collection, the participants will meet the investigators and receive a kit containing ten standardized breakfasts, with two kinds of muffins, and a kit containing a glucose monitor (Abbott Freestyle Libre-CE marked) to monitor their blood sugar levels. The volunteers must have breakfast with the standardized meals and monitor the fasting glucose blood and postprandial glucose blood levels for ten consecutive days. Besides, they must take notes (like a diet diary) about all the food they ingest during the day in ten days of the study.",[29,515,516,257],"Health Behavior","Diabetes",[518,519,520,521,522,523],"Glycemic response","Precision nutrition","Gut Microbiome","Biomarkers","Sequencing analysis","N-of-1 trials","2024-10-22",{"date":526,"type":40},"2024-10-24",{"date":528,"type":40},"2024-06-06",{"date":530,"type":21},"2025-06-30",{"name":532,"class":89},"BiomeHub Biotechnology Company",{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":539,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":243,"minAge":244,"maxAge":17,"enrollmentInfo":541,"targetDuration":4,"studyType":22,"phases":542,"briefSummary":543,"conditions":544,"keywords":552,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":129},"100558914","in-person-lifestyle-program-for-black-adolescent-girls-at-risk-for-type-2-diabetes-100558914","NCT06557317","In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes","Examining the Preliminary Efficacy of an In-Person Lifestyle Intervention for Black Female Adolescent\u002FCaregiver Dyads at Risk for Type 2 Diabetes Mellitus","BGW In-Person","Inclusion Criteria for adolescent participants:\n\n* 12-18 years of age\n* self-identify as Black or African American\n* have obesity (\\>=95th percentile BMI)\n\nExclusion Criteria for adolescent participants:\n\n* pregnant or within 3 months postpartum.\n* participated in a formal weight management program within 6 months prior to study.\n* currently taking medications or diagnosed with a condition known to influence metabolism, physical activity ability, or cognitive function.\n* have previously undergone bariatric surgery.\n* have type 2 diabetes.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.\n\nInclusion Criteria for caregiver participants:\n\n* 18 years or older.\n* proficiency in speaking English.\n* live in the same household as the adolescent who will also be enrolled.\n* prepares the majority (\\>50%) of meals in the household.\n\nExclusion Criteria for caregiver participants:\n\n* pregnant or within 3 months postpartum.\n* unable to speak English or have developmental conditions that interfere with ability to communicate.",{"count":20,"type":21},[163],"The aim of this study is to look at changes in diabetes-related risk factors in Black adolescent girls who are at risk for type 2 diabetes and their primary female caregiver after both participating in a 12-week in-person lifestyle program.",[545,546,64,547,29,257,30,548,549,550,551,221],"Behavior, Adolescent","Childhood Obesity","Pediatric Obesity","Overweight","Overnutrition","Nutrition Disorders","Body Weight",[553,554,555,556,557],"Adolescents","In-Person Lifestyle Program","Diabetes prevention","Black girls","Obesity","2024-08-14",{"date":560,"type":40},"2024-08-16",{"date":562,"type":21},"2024-08",{"date":564,"type":21},"2024-12-31",{"name":566,"class":47},"Cornell University",{"id":568,"slug":569,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":574,"targetDuration":4,"studyType":22,"phases":576,"briefSummary":578,"conditions":579,"keywords":582,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":597},"100550519","phase-4-henagliflozins-impact-on-prediabetes-remission-100550519","NCT06448130","Henagliflozin's Impact on Prediabetes Remission","Effect of Henagliflozin on the Remission of Prediabetes Population: A National Multicenter, Randomized Controlled Study","Inclusion Criteria:\n\n1. Male or female subjects between the ages of 18 and 65 years;\n2. Individuals without hypoglycemic therapy before, including hypoglycemic drugs or traditional Chinese medicine formulations with hypoglycemic effects;\n3. Prediabetic patients as defined by Expert Consensus on Intervention for Prediabetes in Chinese Adults, 2023 Edition:1)Fasting plasma glucose (FPG) between 6.1 and 7.0 mmol\u002FL and\u002For 2-hour postprandial glucose (2h-PPG) between 7.8 and 11.1 mmol\u002FL; 2)And\u002For HbA1c between 5.7% and 6.5%;\n4. Individuals willing to provide written informed consent and can comply with study procedures and follow-up.\n\nExclusion Criteria:\n\n1. Allergic to Henagliflozin;\n2. Previously diagnosed with diabetes;\n3. HbA1c ≥ 6.5% or FPG ≥ 7.0 mmol\u002FL or PPG ≥ 11.1 mmol\u002FL;\n4. Use of GLP-1 receptor agonists, orlistat, or other weight-reducing drugs in the past 3 months;\n5. Fluctuation in weight by 5% or more in the past month;\n6. Use of drugs affecting glucose synthesis, absorption, or metabolism, such as glucocorticoids (e.g., prednisone, dexamethasone), contraceptives, growth hormone, hormonal replacement therapy (estrogen and progesterone), immunosuppressants (e.g., cyclosporine A, tacrolimus), anti-tuberculosis drugs (e.g., isoniazid, rifampicin);\n7. Untreated hyperthyroidism or hypothyroidism, excluding those with normal thyroid function after treatment;\n8. Persistently uncontrolled hypertension (used antihypertensive drugs but was not effectively controlled in the 3 months prior to enrollment) or currently use 3 or more antihypertensive drugs (including diuretics);\n9. Assessed by the investigator to be at high risk of genitourinary system infections, such as history of recurrent urinary tract infections or reproductive system infections, long-term placement of urinary catheters, or history of urological surgery;\n10. Other obesity caused by endocrine disorders, such as Cushing's syndrome;\n11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels \\> 3 times of the upper limit of the normal range (UNL);\n12. eGFR less than 30 mL\u002Fmin\u002F1.73 m2, severe kidney damage, end-stage renal disease or requiring dialysis;\n13. Significant cardiovascular diseases including myocardial infarction, congestive heart failure (≥grade III New York Heart Association), left ventricular ejection fraction≤40%, or cerebrovascular accidents;\n14. Impaired consciousness and various mental health disorders;\n15. Malignant tumors and other serious illnesses;\n16. Pregnant or breast-feeding or planning pregnancy within 24 months;\n17. Enrolled in another clinical trial currently or within the 3 months prior to enrollment;\n18. Identified by the investigator that lacks sufficient motivation to continue the long-term clinical trial (e.g., out-of-town study, work plan, need to care for family members), or considered prefer to withdraw from the trial for non-medical reasons (such as social issues).",{"count":575,"type":21},984,[577],"PHASE4","This clinical trial evaluates the effectiveness of Henagliflozin combined with lifestyle interventions for managing patients with prediabetes. As global prediabetes rates rise, increasing the risk of diabetes and vascular issues, addressing treatment gaps is essential. Henagliflozin, a novel SGLT2 inhibitor developed in China, aims to improve glucose control and metabolic health when paired with lifestyle changes.\n\nThe study's primary objectives include: assessing whether Henagliflozin can achieve normoglycemia in prediabetic patients after 6 months of treatment.\n\nThe trial will compare three groups (Henagliflozin 5mg, 10mg, and a placebo), focusing on efficacy and safety. Participants, assigned randomly, will undergo a 6-month treatment phase and an 18-month follow-up. Regular health assessments will monitor glucose levels, metabolic health, and risks of major complications like cardiovascular events and microvascular diseases, with additional evaluations of C-peptide and insulin changes.\n\nStructured as a multicenter, randomized, double-blind, placebo-controlled study, it involves 984 prediabetic adults across 50 medical institutions in China. This comprehensive approach could redefine prediabetes management by integrating drug therapy with lifestyle modifications.",[580,581,281,29],"PreDiabetes","Prediabetic State",[583,584,585,586,587,29,28],"Prediabetes management","Henagliflozin","SGLT2 inhibitors","Lifestyle interventions","Type 2 diabetes prevention","2024-06-03",{"date":590,"type":40},"2024-06-07",{"date":592,"type":21},"2024-06",{"date":594,"type":21},"2027-12",{"name":596,"class":385},"Shandong Provincial Hospital",50,{"id":599,"slug":600,"hasResults":11,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":608,"briefSummary":609,"conditions":610,"keywords":612,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":617,"completionDateStruct":619,"leadSponsor":621,"locationsCount":129},"100365554","rt-cgm-in-young-adults-at-risk-of-dka-100365554","NCT04039763","RT-CGM in Young Adults at Risk of DKA","Assessment of the Impact of Real-time Continuous Glucose Monitoring on Glycaemic Control in High-risk Adolescents and Young Adults With Insulin-treated Diabetes","YODA","Inclusion Criteria:\n\n* Adolescents and young adults aged 18-25 years\n* Insulin-treated diabetes \\>12 months (on multiple daily injections or insulin pump therapy)\n* HbA1c \\> 75 mmol\u002Fmol (9%) or 1 or more DKA admissions in the last 12 months or 1 or more admissions with uncontrolled blood glucose levels in the last 12 months.\n* Naïve to RT-CGM - except for short periods for use for diagnosis or monitoring purposes.\n* Use of prior flash glucose monitoring is permittable\n\nExclusion Criteria:\n\n* Chronic kidney disease eGFR \\\u003C30ml\u002Fmin\n* Pregnant or planning pregnancy\n* Breastfeeding\n* Have active malignancy or under investigation for malignancy\n* Severe visual impairment\n* Reduced manual dexterity\n* Unable to participate due to other factors, as assessed by the Chief Investigator","25 Years",{"count":5,"type":21},[163],"Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses.\n\nHypothesis: RT-CGM provided to young adults with suboptimal blood glucose control, has a beneficial impact on HbA1c and hospital admissions for high blood glucoses. We will use data from this pilot work to inform a larger powered study to address this knowledge gap.",[221,611,29,257,31,30],"Diabetes Mellitus, Type 1",[613],"Type 1 Diabetes Mellitus","2022-06-23",{"date":616,"type":40},"2022-06-24",{"date":618,"type":40},"2020-09-03",{"date":620,"type":21},"2022-06-30",{"name":622,"class":47},"Imperial College London"]